MyMD Pharmaceuticals (MYMD) News Today $1.92 +0.06 (+3.23%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 22, 2024 | businesswire.comMyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.July 15, 2024 | investorplace.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024June 17, 2024 | businesswire.comMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical OfficerMay 21, 2024 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 17, 2024 | investorplace.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023April 30, 2024 | msn.comGold prices fall as rate jitters mount ahead of Fed meetingApril 18, 2024 | msn.comMorning Bid: Dollar bulls enter the China shopApril 9, 2024 | investorplace.comWhy Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?April 7, 2024 | uk.investing.comRecursion Pharmaceuticals CEO sells over $1.16m in stockMarch 28, 2024 | msn.comExclusive-Software industry calls for more UK Government supportMarch 5, 2024 | finance.yahoo.comMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingFebruary 22, 2024 | benzinga.comMyMD Pharmaceuticals Stock (NASDAQ:MYMD), Short Interest ReportFebruary 15, 2024 | marketbeat.comTrading was temporarily halted for "MYMD" at 07:02 PM with a stated reason of "News pending."February 13, 2024 | msn.comMyMD Pharmaceuticals down after announcing reverse stock splitDecember 8, 2023 | morningstar.comMyMD Pharmaceuticals Inc Ordinary SharesDecember 7, 2023 | msn.comMyMD to begin Phase II trial of rheumatoid arthritis therapyOctober 20, 2023 | benzinga.comFive Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBDOctober 19, 2023 | finance.yahoo.comMyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory PainOctober 18, 2023 | bizjournals.comBaltimore pharmaceutical company faces delisting from the NasdaqAugust 14, 2023 | finance.yahoo.comFDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)July 31, 2023 | marketwatch.comMyMD Shares Surge on Positive Sarcopenia Study Results >MYMDJuly 31, 2023 | finance.yahoo.comMyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related FrailtyJuly 31, 2023 | marketbeat.comTrading was temporarily halted for "MYMD" at 08:07 AM with a stated reason of "News pending."May 17, 2023 | finance.yahoo.comWill MyMD Pharmaceuticals (NASDAQ:MYMD) Spend Its Cash Wisely?March 22, 2023 | benzinga.comMyMD Pharmaceuticals And Charles River Present Data For Next Generation, Oral TNF-α Inhibitor MYMD-1 In Rheumatoid ArthritisMarch 20, 2023 | finance.yahoo.comMyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid ArthritisMarch 8, 2023 | msn.comMyMD Joins LOT Network To Protect Company And Shareholders From Patent TrollsMarch 2, 2023 | finance.yahoo.comMyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed ChemicalFebruary 28, 2023 | finance.yahoo.comMyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual MeetingFebruary 21, 2023 | finance.yahoo.comMyMD Announces $15 Million Offering with Existing InvestorsDecember 6, 2022 | finance.yahoo.comADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022November 14, 2022 | finance.yahoo.comMyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug ResearchSeptember 22, 2022 | reuters.comHealthcare & PharmaceuticalsSeptember 20, 2022 | finance.yahoo.comMyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanAugust 31, 2022 | stockhouse.comMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD(TM) CompoundAugust 30, 2022 | marketbeat.comShort Interest in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Grows By 24.8%MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD - Get Rating) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 699,200 shares, a growth of 24.8% from the July 31st total of 560,200 shares. Approximately 2.0% of the company's shares are short sold. Based on an average daily trading volume, of 255,500 shares, the short-interest ratio is presently 2.7 days.August 30, 2022 | finance.yahoo.comMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ CompoundAugust 29, 2022 | finance.yahoo.comMyMD Pharmaceuticals, Inc. (MYMD)August 5, 2022 | benzinga.comData Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological SciencesJuly 29, 2022 | finance.yahoo.comIs MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders?July 26, 2022 | finance.yahoo.comNew Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsightJuly 26, 2022 | finance.yahoo.comMyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanJuly 12, 2022 | finance.yahoo.comMyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic ConditionsJuly 7, 2022 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsJune 18, 2022 | morningstar.comMyMD Pharmaceuticals Inc Ordinary Shares - Stock ChartApril 5, 2022 | finance.yahoo.comMyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanFebruary 23, 2022 | finance.yahoo.comMyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanJanuary 5, 2022 | seekingalpha.comMyMD Pharma secures new U.S. patent covering MYMD-1 in a method of treating sarcopeniaJanuary 5, 2022 | finance.yahoo.comMyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Former Hedge Fund Manager Issues Crash Prediction (Ad)Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich. Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. MYMD Media Mentions By Week MYMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYMD News Sentiment▼0.430.61▲Average Medical News Sentiment MYMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYMD Articles This Week▼20▲MYMD Articles Average Week Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CDIO News BMRA News VRAX News NAVB News ALGS News DRRX News IOBT News LIFE News ATOS News CADL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYMD) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.